BRIDGE BIOTHERAPEUTICS, INC.

Other languages Bridge Biotherapeutics, Inc.

Equities

A288330

KR7288330004

End-of-day quote Korea S.E. Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
2,555 ^KRW	+12.06%		+10.37%	-22.22%

28/03	Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade	CI
26/03	Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade	29/03
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology	27/03
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy	14/12
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC	31/23/31
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis	26/23/26
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting	19/23/19
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis	13/23/13
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401	21/23/21
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis	08/22/08
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022	02/22/02
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877	16/22/16
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022	10/22/10
Bridge Biotherapeutics, Inc. Presents Preclinical Data of BBT-207 at the AACR Annual Meeting 2022	13/22/13
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics	08/22/08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer